$LPNT (LifePoint Health, Inc.)

$LPNT {{ '2016-01-04T14:08:40+0000' | timeago}} • Announcement

Healthcare services provider $LPNT said it completed its acquisition of St. Francis Hospital. Under this acquisition, the company said it has satisfied St. Francis' financial obligations, including paying off its loan from the U.S. Department of Housing and Urban Development.

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$GILD {{ '2018-01-18T17:34:32+0000' | timeago}} • Announcement

Kite, a $GILD company, has entered into a clinical trial collaboration with Pfizer, Inc. to evaluate the safety and efficacy of the combination of Yescarta and Pfizer's utomilumab, in patients with refractory large B-cell lymphoma. A multi-center Phase 1/2 study sponsored by Kite is expected to begin in 2018.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$MD {{ '2018-01-10T15:20:12+0000' | timeago}} • Announcement

$MD announced the acquisition of Tri-Valley Neonatal Medical Group, Inc., a private neonatology physician practice based in California. This was a cash transaction and it is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed.

$SEM {{ '2018-01-09T18:17:01+0000' | timeago}} • Announcement

$SEM announced a JV agreement with Banner Health to combine operations of more than 38 physical therapy centers in Arizona and four acute inpatient rehabilitation hospitals in Phoenix. Banner Health will be the majority owner and $SEM will serve as managing partner.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$CELG {{ '2018-01-08T19:25:23+0000' | timeago}} • Announcement

$CELG announced preliminary results for 4Q17 and FY17. Celgene also provided the outlook for FY18 and reaffirmed FY20 guidance. The company is expected to finalize these results when it announces the earnings results on Jan. 25, 2018.

$SEM {{ '2018-01-08T18:16:59+0000' | timeago}} • Announcement

$SEM expects consolidated net operating revenues for full year 2018 to be $5-5.2Bil. Adjusted EBITDA is expected to be $630-660MM. $SEM expects fully diluted income per common share for full year 2018 to be $0.97-1.12.

$CELG {{ '2018-01-08T14:00:46+0000' | timeago}} • Announcement

$CELG agreed to acquire start-up firm Impact Biomedicines for an upfront payment of $1.1Bil. Under the deal terms, Celgene will further pay up to $1.25Bil on Impact's cancer drug Fedratinib getting FDA's approvals. If the global annual net sales of the drug exceed $5Bil, Celgene will pay a maximum of $4.5Bil. The deal is expected to close in 1Q18.

$THC {{ '2018-01-05T17:28:17+0000' | timeago}} • Announcement

$THC and St. Luke’s Hospital, an independent, non-profit healthcare provider, have entered into a definitive agreement for St. Luke’s to purchase Des Peres Hospital as well as Tenet-owned physician practices and other hospital-affiliated operations in St. Louis. The transaction is expected to be completed early in 2018.

$AMGN {{ '2018-01-05T14:22:45+0000' | timeago}} • Announcement

$AMGN gets US FDA's approval for the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma.

$THC {{ '2018-01-04T22:16:28+0000' | timeago}} • Announcement

$THC and Baylor Scott & White Health plan to restructure their JV arrangements for three North Texas hospitals by spring of 2018. Baylor Scott & White will acquire $THC’s minority interest in Baylor Scott & White - Centennial and Baylor Scott & White - Lake Pointe. Baylor Scott & White - Sunnyvale will become part of Texas Health Ventures Group.

$THC {{ '2017-12-26T17:43:20+0000' | timeago}} • Announcement

$THC and Baylor Scott & White Health have agreed to sell Baylor Scott & White Medical Center - White Rock, a 218-bed hospital located in Dallas, Texas, to Pipeline Health, LLC. The hospital is part of a JV partnership with Baylor Scott & White Health, in which $THC is the minority owner. The transaction is expected to be completed in 1Q18.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$CELG {{ '2017-12-22T14:11:59+0000' | timeago}} • Announcement

$CELG's cancer drug Revlimid fails to meet the endpoint in the first Phase 3 trial. Celgene said that additional analyses are ongoing and it would present the complete analyzed data in a future medical conference. Revlimid contributed 63% of Celgene's revenue in their recently ended third quarter.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$HUM {{ '2017-12-19T15:27:46+0000' | timeago}} • Announcement

$HUM signed a definitive agreement to acquire a 40% minority interest in the Kindred at Home Division of $KND for an estimated cash consideration of approximately $800MM. Humana does not anticipate a material impact to earnings in 2017 from this pending transaction.

$KND {{ '2017-12-19T13:44:51+0000' | timeago}} • Announcement

$KND's BoD approved a definitive agreement whereby it will be acquired by a consortium of three companies: TPG Capital, Welsh, Carson, Anderson & Stowe and $HUM for about $4.1Bil in cash including the assumption or repayment of net debt. The transaction is expected to close during the summer of 2018.

$THC {{ '2017-12-19T13:06:16+0000' | timeago}} • Announcement

For FY18, $THC expects its net income to be in the range of $65-70MM with EPS of about $0.63-0.68. Adj. EPS is expected to be about $1.07-1.36. Net operating revenue is expected to be about $17.8-18.2Bil.

$THC {{ '2017-12-19T13:04:06+0000' | timeago}} • Announcement

$THC said it would explore a sale of its subsidiary Conifer. The company expects to make a decision regarding the sale during the first half of 2018. Goldman, Sachs & Co. LLC as its financial advisor and Kirkland & Ellis LLP are the legal advisor.

Recent Transcripts

ENSG (The Ensign Group, Inc.)
Thursday, November 9 2017 - 6:00pm
FVE (Five Star Quality Care Inc.)
Thursday, November 9 2017 - 3:00pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
DVA (DaVita HealthCare Partners Inc.)
Tuesday, November 7 2017 - 10:00pm
THC (Tenet Healthcare Corp.)
Tuesday, November 7 2017 - 3:00pm
KND (Kindred Healthcare Inc.)
Tuesday, November 7 2017 - 2:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
SEM (Select Medical Holdings Corporation)
Friday, November 3 2017 - 1:00pm
FMS (Fresenius Medical Care AG & Co. KGAA)
Thursday, November 2 2017 - 8:30pm
CYH (Community Health Systems, Inc.)
Thursday, November 2 2017 - 3:00pm
MD (MEDNAX, Inc.)
Wednesday, November 1 2017 - 2:00pm
MGLN (Magellan Health, Inc.)
Wednesday, November 1 2017 - 2:00pm
EVHC (Envision Healthcare Holdings, Inc.)
Wednesday, November 1 2017 - 12:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
HCA (HCA Holdings, Inc.)
Tuesday, October 31 2017 - 2:00pm
LPNT (LifePoint Health, Inc.)
Friday, October 27 2017 - 2:00pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
UHS (Universal Health Services Inc.)
Thursday, October 26 2017 - 1:00pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm

AlphaGraphics you may like